784b2763-b9be-4b7f-84b0-f5ec6f784717
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 61.5797399041752
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.570
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.440
- INTERFERON_ALPHA_RESPONSE+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.270
- DNA_REPAIR+0.260
- OXIDATIVE_PHOSPHORYLATION+0.250
- INTERFERON_GAMMA_RESPONSE+0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.370
- ANDROGEN_RESPONSE-0.340
- HEME_METABOLISM-0.290
- PROTEIN_SECRETION-0.290
- TGF_BETA_SIGNALING-0.290
- APICAL_SURFACE-0.280
- ESTROGEN_RESPONSE_EARLY-0.280
- XENOBIOTIC_METABOLISM-0.260
- FATTY_ACID_METABOLISM-0.220
- UV_RESPONSE_DN-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-QK-A6IG-01A-11R-A31N-07 | — | — | 0.841 |
| 2 | MNG211 | — | — | 0.793 |
| 3 | TCGA-CV-A6JZ-01A-11R-A31N-07 | — | — | 0.758 |
| 4 | BS_HE57E1RP | Med | Medulloblastoma | 0.755 |
| 5 | TCGA-21-1083-01A-01R-0692-07 | — | cohortMD1 | 0.750 |
| 6 | MNG914 | — | — | 0.750 |
| 7 | TCGA-OR-A5LC-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.746 |
| 8 | 48e3eab5-b82e-4dbb-88d2-e5cfe295fa88 | — | — | 0.746 |
| 9 | BS_MMNRZ1EQ | ATRT | — | 0.744 |
| 10 | MNG802 | — | — | 0.740 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.570 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.160 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.150 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |